Radioactive 'Trojan Horse' targets advanced prostate cancer in new trial
NCT ID NCT06526299
Summary
This study is testing a new treatment for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapies. The treatment uses a radioactive drug that seeks out and attaches to prostate cancer cells to deliver radiation directly to tumors. Researchers want to see if this targeted approach can better control the cancer and improve outcomes for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Olive View-University of California Los Angeles Medical Center
NOT_YET_RECRUITINGSylmar, California, 91342, United States
Contact
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact
Conditions
Explore the condition pages connected to this study.